Compare Amphastar Pharmaceuticals Inc (AMPH) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs CarMax, Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while CarMax, Inc trades at $53.68 (market cap $7.59B). The key difference: CarMax, Inc is far larger — about 9.2× Amphastar Pharmaceuticals Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | KMX | |
|---|---|---|
Market Cap | $826.08M | $7.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $65.20 |
52-Week Low | $16.87 | $30.88 |
Enterprise Value | $1.22B | $26.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CarMax (KMX) trades at $53.49, up 4.86% with a bullish technical signal. The stock shows mixed fundamentals with a P/E of 33.22 and net margin of 0.84%, though recent Q1 2026 earnings beat expectations. Revenue trends downward from $31.9B in 2022 to $26.4B in 2025, while net cash flow turned negative at -$290M. Analyst sentiment is cautious with 62.9% hold ratings and a $48.91 consensus target below current price. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr.
KMX presents a speculative opportunity amid transition, with potential upside from execution of digital and cost initiatives. Key risks include margin pressure, high debt load ($18.1B long-term), and investigation concerns. Near-term resistance at $53, support at $49. Wall Street remains neutral pending clearer turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
